ImmunoGen Beheer

Beheer criteriumcontroles 2/4

De CEO ImmunoGen is Mark Enyedy, benoemd in May2016, heeft een ambtstermijn van 6.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.44M, bestaande uit 9.9% salaris en 90.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde € 2.10M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 10.8 jaar.

Belangrijke informatie

Mark Enyedy

Algemeen directeur

US$7.4m

Totale compensatie

Percentage CEO-salaris	9.9%
Dienstverband CEO	6.5yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	2.4yrs
Gemiddelde ambtstermijn bestuur	10.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Mark Enyedy's beloning veranderd ten opzichte van ImmunoGen's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	n/a	n/a	-US$201m
Jun 30 2022	n/a	n/a	-US$161m
Mar 31 2022	n/a	n/a	-US$129m
Dec 31 2021	US$7m	US$735k	-US$139m
Sep 30 2021	n/a	n/a	-US$71m
Jun 30 2021	n/a	n/a	-US$56m
Mar 31 2021	n/a	n/a	-US$49m
Dec 31 2020	US$5m	US$714k	-US$44m
Sep 30 2020	n/a	n/a	-US$71m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$89m
Dec 31 2019	US$4m	US$710k	-US$104m
Sep 30 2019	n/a	n/a	-US$151m
Jun 30 2019	n/a	n/a	-US$176m
Mar 31 2019	n/a	n/a	-US$174m
Dec 31 2018	US$9m	US$687k	-US$169m
Sep 30 2018	n/a	n/a	-US$140m
Jun 30 2018	n/a	n/a	-US$150m
Mar 31 2018	n/a	n/a	-US$117m
Dec 31 2017	US$3m	US$670k	-US$96m
Sep 30 2017	n/a	n/a	-US$117m
Jun 30 2017	n/a	n/a	-US$105m
Mar 31 2017	n/a	n/a	-US$142m
Dec 31 2016	US$569k	US$325k	-US$157m

Compensatie versus markt: De totale vergoeding ($USD 7.44M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.42M ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Enyedy (58 yo)

6.5yrs

Tenure

US$7,440,507

Compensatie

Mr. Mark Joseph Enyedy is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and served as its Interim Pr...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Enyedy	President	6.5yrs	US$7.44m	0.20% € 2.1m
Susan Altschuller	Senior VP & CFO	2.3yrs	US$1.53m	0% € 0
Anna Berkenblit	Senior VP & Chief Medical Officer	7.6yrs	US$2.51m	0.050% € 531.7k
Stacy Coen	Senior VP & Chief Business Officer	2.4yrs	US$1.61m	0.0032% € 34.6k
Renee Lentini	VP of Finance & Principal Accounting Officer	1.8yrs	geen gegevens	0.0083% € 88.3k
Courtney O'Konek	Senior Director of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Joseph Kenny	VP, Acting General Counsel	no data	geen gegevens	geen gegevens
Audrey Bergan	Senior VP & Chief HR Officer	4.3yrs	geen gegevens	geen gegevens
Theresa Wingrove	Senior Vice President of Regulatory Affairs & Quality	no data	US$1.27m	0.037% € 396.5k
Mary Huizinga	Senior VP & Head of Medical Affairs	less than a year	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van IMU wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Enyedy	President	6.5yrs	US$7.44m	0.20% € 2.1m
Stephen McCluski	Independent Chairman	15.6yrs	US$406.07k	0% € 0
Dean Mitchell	Independent Director	10.8yrs	US$365.07k	0.042% € 448.5k
Kristine Peterson	Independent Director	10.8yrs	US$375.07k	0% € 0
Helen Thackray	Independent Director	1.2yrs	US$374.79k	0% € 0
Richard Wallace	Independent Director	15yrs	US$368.07k	0% € 0
Stuart Arbuckle	Independent Director	4.8yrs	US$358.07k	0% € 0
Mark A. Goldberg	Independent Director	11yrs	US$365.07k	0.024% € 259.4k
Tracey McCain	Independent Director	less than a year	US$351.30k	0% € 0

10.8yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van IMU zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.8 jaar).

ImmunoGen Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ASCO

Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review

First quarter 2022 earnings released: US$0.095 loss per share (vs US$0.17 loss in 1Q 2021)

ImmunoGen, Inc. Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunoGen, Inc. Appoint Executives

Forecast to breakeven in 2024

ImmunoGen Appoints Mimi Huizinga as Senior Vice President and Head of Medical Affairs

Forecast to breakeven in 2024

ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH

Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.13 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.15 loss per share (vs US$0.14 loss in 2Q 2020)

ImmunoGen, Inc. Announces Mature Data from Forward II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin in Recurrent Ovarian Cancer, Regardless of Platinum Status

First quarter 2021 earnings released: US$0.17 loss per share (vs US$0.17 loss in 1Q 2020)

ImmunoGen, Inc. Provides Revenue Guidance for the Year of 2021

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

Executive Officer has left the company

Full year 2020 earnings released: US$0.25 loss per share (vs US$0.70 loss in FY 2019)

Revenue beats expectations

New 90-day high: €6.39

ImmunoGen, Inc. Enters into Collaboration and Option Agreement with Subsidiary of Jazz Pharmaceuticals plc

New 90-day high: €5.29

ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting

Third quarter 2020 earnings released: US$0.13 loss per share

Revenue beats expectations

New 90-day high: €4.98

ImmunoGen, Inc. Announces Executive Changes, Effective on January 1, 2021

ImmunoGen and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Announces Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China

New 90-day high: €4.63

ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO

New 90-day low - €2.99

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur